Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rockwell MedicalFRA:RWM 55 12-1 Month Momentum % is -38.74% as of Aug. 19, 2026. GuruFocus rates FRA:RWM with a GF Score™ of 55/100 and a GF Value™ of €5.73 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,016 Drug Manufacturers companies, Rockwell Medical ranks worse than 83.86% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-19), Rockwell Medical's 12-1 Month Momentum % is -38.74%.
The industry rank for Rockwell Medical's 12-1 Month Momentum % or its related term are showing as below:
FRA:RWM's 12-1 Month Momentum % is ranked worse than 83.86% of 1016
companies
in the Drug Manufacturers industry
Industry Median: -14.32
vs FRA:RWM: -38.74
Rockwell Medical (FRA:RWM) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Rockwell Medical 12-1 Month Momentum % Related Terms
FRA:RWM vs BTAI, MRMD, TXMD: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's 12-1 Month Momentum % falls into.
Rockwell Medical (FRA:RWM) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -38.74% mean?
Rockwell Medical (FRA:RWM) has a 12-1 Month Momentum % of -38.74% as of Aug. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #852 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 83.9%.
Is Rockwell Medical's 12-1 Month Momentum % too high?
Rockwell Medical's current 12-1 Month Momentum % is -38.74%. Based on the distribution chart, Rockwell Medical ranks #852 out of 1016 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's 12-1 Month Momentum % compare to BTAI and MRMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #852 out of 1016 companies for 12-1 Month Momentum %. This places Rockwell Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Rockwell Medical and its competitors. Rockwell Medical's current 12-1 Month Momentum % is -38.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Fairly Valued. The stock's GF Value™ is €5.73, compared to a current price of €5.25 — trading 8.4% below its estimated fair value. The current 12-1 Month Momentum % is -38.74%. Rockwell Medical's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current 12-1 Month Momentum % is -38.74% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of €5.25 is trading 8.4% below its estimated GF Value™ of €5.73.
GuruFocus considers Rockwell Medical to be Fairly Valued.
Key valuation signals for FRA:RWM:
12-1 Month Momentum %: -38.74%
GF Value™: €5.73 vs. price of €5.25 (8.4% below fair value)
No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
55GF Score
Get the complete analysis for FRA:RWM
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWM has been successfully added to your 
